Moreover, some of the therapeutic benefits of a medium chain fatty α- lipoic acid (ALA) in the treatment of DPN may be ascribed to its ability to increase blood flow to the nerves via antioxidant processes and to reduce endothelial dysfunction by lowering plasma levels of interleukin 6 and plasminogen activator 1. This evidence concerns the gene IL6 and endothelial dysfunction.